Erythrodermic psoriasis: Epidemiological clinical and therapeutic features about 60 cases

##plugins.themes.academic_pro.article.sidebar##

Published Dec 12, 2011
Download
pdf
Vol. 89 No. 11 (2011): Issue Nov 2011

##plugins.themes.academic_pro.article.main##

Abdelmoati Hawilo
Inès Zaraa
Rym Benmously
Amel Mebazaa
Dalenda El Euch
Mourad Mokni
Amel Ben Osman

Abstract

Background: the erythrodermic psoriasis (EP) is a rare but severe form of psoriasis that may be potentially life-threatening.
Aim: To study the characteristics of this severe form of psoriasis.
Methods:We present a retrospective study, including all cases of EP followed in the dermatology department of the La Rabta hospital of Tunis over a 31-year-period from January, 1980 to June, 2010.
Results: sixty patients were included, concerning 46 men and 14 women, with an average age of 53.7. A history of psoriasis was reported in 78 % of the cases. A triggering factor was found in 53 % of the cases. Systemic treatments were required in 55 % of cases. An improvement was noted in 69.4 % of the cases. A recurrence of the EP was observed in 15% of the cases. Three cases of sepicemia and one of stroke were noted.
Conclusion: Erythrodermic psoriasis is the most common etiology of erythroderma. It represents more than half of severe psoriasis. As shown in our study it affects mainly adults’ males. It complicates usually a common psoriasis. Septic and thromboembolic complications ones justify a close follow up.

Keywords:

Psoriasis, erythroderma, retinoid

##plugins.themes.academic_pro.article.details##

References

  1. Hasan T, Jansen CT. Erythroderma: a follow-up of fifty cases. J Am Acad Dermatol 1983; 8: 836-840.
  2. Sehgal VN, Srivastava G. Exfoliative dermatitis. A prospective study of 80 patients. Dermatologica 1986; 173: 278-84.
  3. Thestrup-Pedersen K, Halkier-Sorensen L, Sogaard H, Zachriae H. Exfoliative dermatitis of unknown etiology: A description and follow-up of 38 patients. J Am Acad Dermatol 1988;18:1307-312.
  4. Vasconcellos C, Dominguez PP, Aoki V, et al. Erythroderma: analysis of 247 cases. Rev Saudi Publica1995; 29: 177-182.
  5. Chaudhary A, Gupte PD. Erythroderma: a study of incidence and aetiopathogenesis. Indian J Dermatol Venereol Leprol 1997; 63: 38-39
  6. Sigurdsson V, Toonstra J, Hezemans-Boer M, et al. A clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol 1996; 35: 53-57.
  7. Pal S, Haroon TS. Erythroderma: a clinico-etiologic study of 90 cases. Int J Dermatol 1998; 37: 104-107.
  8. Morar N, Dlova N, Gupta AK, Naidoo DK, Aboobaker J, Ramdial PK. Erythroderma: a comparison between HIV positive and negative patients. Int J Dermatol 1999; 38: 895-900.
  9. Sudho R, Hussain SB, Bellraj E, et al. Clinicopathological study of exfoliative dermatitis. Indian J Dermatol Venereol Leprol 2003; 69: 30-31.
  10. 10-Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: A clinical study of 97 cases. BMC Dermatology 2005; 5: 5.
  11. Torres-Camacho P, Tirado-Sanchez A, Ponce-Olivera RM. Erythroderma: Clinical and laboratory follow up of 66 Mexican patients. Indian J Dermatol Venereol Leprol 2009; 75:522-23.
  12. El Euch D, Zeglaoui F, Benmously R, et al. Erythroderma. Aclinical study of 127 cases and review of the literature. Exog Dermatol 2003; 2:234-39.
  13. Benmously MR, Mokni M, Zouari B, et al. Erythroderma in adults: a report of 80 cases. Int J Dermatol 2005; 44: 731-35.
  14. Khaled A, Sellami A, Fazaa B, Kharfi M, Zeglaoui F, Kammoun MR. Acquired erythroderma in adults: a clinical and prognostic study. J Eur Acad Dermatol Venerol 2010; 24: 781-88.
  15. Bachot N. Erythrodermie: Encycl Med Chir (paris), Dermatologie, 98-160 A-10, 2002.
  16. Goeckerman WH, O'Leary PA. Erythroderma psoriaticum: a review of twenty-two cases. JAMA 1932; 99: 2102-105.
  17. Marks J. Erythrodermas and uric acid aberrations in psoriasis. In: Farber EM, Cox AJ, eds, Psoriasis: proceedings of the international symposium. Stanford: Stanford University Press, 1971: 89 -98.
  18. Boyd AS, Menter A. Erythrodermic psoriasis: precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989; 21:985-91.
  19. Jalal O, Houass S, Laissaoui K, Hocar O, Charioui S, Amal S. Formes graves de psoriasis: 160 cas. Ann Dermatol Venereol 2005; 132: 126-28.
  20. Roth PE, Grosshans E, Bergoend H. Psoriasis: development and fatal complications. Ann Dermatol Venereol 1991;118: 97-105.
  21. Wilson DC, Jester JD, King LE Jr. Erythroderma and exfoliative dermatitis. Clin Dermatol 1993; 11: 67-72.
  22. Zip C, Murray S, Walsh NMG. The specificity of histopathology in erythroderma. J Cutan Pathol 1993; 20: 393-398.
  23. Walsh NMG, Prokopetz R, Tron VA, et al. Histopathology in erythroderma: review of a series of cases by multiple observers. J Cutan Pathol 1994; 21: 419-423
  24. Prakash BV, Sirisha NL, Satyanarayana VV, Sridevi L, Ramachandra BV. Aetiopathological and clinical study of erythroderma. J Indian Med Assoc. 2009; 107: 100, 102-103.
  25. Mebazaa A, El Asmi M, Zidi W et al. Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. J Eur Acad Dermatol Venereol 2011; 25: 705-9.
  26. Aalto-Korte K, Turpeinen M. Quantifying systemic absorption of topical hydrocortisone in erythroderma. Br J Dermatol 1995,133: 403-408
  27. Marks J. Erythroderma and its management. Clin Exp Dermatol 1982;7: 415-22.
  28. Bonnetblanc JM. Erythrodermies: orientation diagnostique. Ann Dermatol Vénérol 2008; 135; SF214—F217.
  29. Rosenbach M, Hsu S, Korman NJ.et al. Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62: 655-62.
  30. Qureshi AA, Husni ME, Mody E. Psoriatic Arthritis and Psoriasis. Need for a Multidisciplinary Approach. Semin Cutan Med Surg 2005; 24: 46-51.
  31. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Management of erythrodermic psoriasis with low-dose cyclosporine. Dermatology 1993; 187: 30-37.
  32. Collins P, Rogers S. The efficacy of methotrexate in psoriasis a review of 40 cases. Clin Exp Dermatol 1992; 17: 257-60.
  33. Van Dooren-Greebe RJ, Kuijpers AL. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204-10.
  34. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years'experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol 2000; 14: 382-88.
  35. Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica 1988;176:182-90.
  36. Poulalhon N, Begon E, Lebbe C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007; 156: 329-36.
  37. Esposito M, Mazzotta A. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol 2006; 155: 156-59.
  38. Takahashi MDF, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol 2007; 157: 828-31.
  39. Heikkila H, Ranki A, Cajanus S, Karvonen SL. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol 2005; 141: 1607-10.
  40. Korstanje MJ, Bessems PJ, van de Staak WJ. Combination therapy ciclosporin-etretinate effective in erythrodermic psoriasis. Dermatologica 1989; 179: 194
  41. Kokelj F, Plozzer C, Torsello P, Trevisan G. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports). J Eur Acad Dermatol Venereol 1998; 11: 177- 79.
  42. Brechtel B, Wellenreuther U, Toppe E, Czarnetski BM. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis. J Am Acad Dermatol 1994;30: 1023-24
  43. Aydin F, Canturk T, Senturk N, Turanli AY. Methotrexate and cyclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol 2006; 31: 520-24.
  44. Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis 2006;78: 178-80.